A case of lung adenocarcinoma with a novel CD74‐ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib

• Main Authors: Mizuha Haraguchi Hashiguchi, Takashi Sato, Rinako Watanabe, Junko Kagyo, Tomohiko Matsuzaki, Hideharu Domoto, Terufumi Kato, Yoshiro Nakahara, Tomoyuki Yokose, Yukihiko Hiroshima, Tetsuya Shiomi
• Format: Article
• Language: English
• Published: Wiley 2021-09-01
• Series: Thoracic Cancer
• Subjects: CD74‐ROS1 fusion variant; crizotinib; entrectinib; lung adenocarcinoma; next‐generation sequencing
• Online Access: https://doi.org/10.1111/1759-7714.14093
• ISSN: 1759-7706; 1759-7714

Abstract ROS1 rearrangements are found in 1–2% of patients with non‐small‐cell lung cancer. The detection of the rearrangements is crucial since clinically effective molecular targeted drugs are available for them. We present a case of lung adenocarcinoma with a previously unknown ROS1‐CD74 fusion variant, CD74 exon 3 fused to ROS1 exon 34, which was not detected by a conventional RT‐PCR‐based test for ROS1 fusion gene detection but identified by hybrid capture‐based next‐generation sequencing. This tumor responded to crizotinib initially and to entrectinib after relapse with brain metastasis, indicating the oncogenic activity of this novel fusion variant.